WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

This group comprises all hormonal preparations for systemic use, except:

- Insulins, see A10.
- Anabolic steroids, see A14.
- Catecholamines, see C01C and R03C.
- Sex hormones, see G03.
- Sex hormones used in treatment of neoplastic diseases, see L02.
- Metreleptin used for treatment of complications of leptin deficiency in patients with generalised lipodystrophy is classified in A16AA.

The DDDs are generally based on the treatment or diagnosis of endocrine disorders.


H05 CALCIUM HOMEOSTASIS

Drugs acting on calcium homeostasis are classified in this group.

Vitamin-D preparations, see A11CC.


H05B ANTI-PARATHYROID AGENTS
H05BX Other anti-parathyroid agents

Paricalcitol and doxercalciferol indicated for the prevention and treatment of secondary hyperparathyroidism are classified here.

Modified-release oral formulations of calcifediol indicated for the treatment of hyperparathyroidism are classified in A11CC06.

The DDD for cinacalcet is based on the treatment of secondary hyperparathyroidism.


    ATC code  Name  DDD  U Adm.R Note
    H05BX01 cinacalcet 60 mg 

List of abbreviations

Last updated: 2018-12-13